About ASTRAZENECA | DxMultiomics

ASTRAZENECA

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

News Releases

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

_↗ astrazeneca-us.com

Apr 11, 2024

Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours

_↗ astrazeneca.com

Apr 6, 2024

AstraZeneca: Voydeya approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular haemolysis in adults with the rare disease PNH

_↗ astrazeneca.com

Apr 1, 2024

AstraZeneca Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer

_↗ astrazeneca.com

Feb 19, 2024

AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases

_↗ astrazeneca.com

Dec 26, 2023

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

_↗ astrazeneca.com

Nov 20, 2023

Tagrisso plus chemotherapy granted Priority Review in the US for patients with EGFR-mutated advanced lung cancer

_↗ astrazeneca.com

Oct 16, 2023

Forxiga approved in China to reduce the risk of cardiovascular death and hospitalisation in adult patients with symptomatic chronic heart failure

_↗ astrazeneca.com

Aug 18, 2023

Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies

_↗ astrazeneca.com

Jul 28, 2023

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.